Published in Biol Psychiatry on February 01, 2005
Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry (2013) 4.12
Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology (2010) 2.97
Electroencephalographic alpha measures predict therapeutic response to a selective serotonin reuptake inhibitor antidepressant: pre- and post-treatment findings. Biol Psychiatry (2007) 1.90
Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx (2006) 1.19
Amplitude of low-frequency oscillations in first-episode, treatment-naive patients with major depressive disorder: a resting-state functional MRI study. PLoS One (2012) 1.09
Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches. Am J Psychiatry (2015) 1.04
Chronic vagus nerve stimulation for treatment-resistant depression decreases resting ventromedial prefrontal glucose metabolism. Neuroimage (2008) 0.99
Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. Dialogues Clin Neurosci (2008) 0.99
Differential effects of serotonergic and noradrenergic antidepressants on brain activity during a cognitive control task and neurofunctional prediction of treatment outcome in patients with depression. J Psychiatry Neurosci (2010) 0.96
Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment. Psychiatry Res (2009) 0.94
Pretreatment cerebral metabolic activity correlates with antidepressant efficacy of vagus nerve stimulation in treatment-resistant major depression: a potential marker for response? J Affect Disord (2012) 0.93
Neuroimaging-based biomarkers for treatment selection in major depressive disorder. Dialogues Clin Neurosci (2014) 0.91
Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift. Front Behav Neurosci (2015) 0.89
Effects of duloxetine treatment on brain response to painful stimulation in major depressive disorder. Neuropsychopharmacology (2010) 0.86
Baseline brain metabolism in resistant depression and response to transcranial magnetic stimulation. Neuropsychopharmacology (2011) 0.84
Chronic treatment of astrocytes with therapeutically relevant fluoxetine concentrations enhances cPLA2 expression secondary to 5-HT2B-induced, transactivation-mediated ERK1/2 phosphorylation. Psychopharmacology (Berl) (2009) 0.83
Determination of hemispheric emotional valence in individual subjects: a new approach with research and therapeutic implications. Behav Brain Funct (2007) 0.83
Brain SPECT Imaging in Complex Psychiatric Cases: An Evidence-Based, Underutilized Tool. Open Neuroimag J (2011) 0.82
Medial prefrontal cortex activity during memory encoding of pictures and its relation to symptomatic improvement after citalopram treatment in patients with major depression. J Psychiatry Neurosci (2010) 0.82
Fluoxetine and all other SSRIs are 5-HT2B Agonists - Importance for their Therapeutic Effects. Curr Neuropharmacol (2014) 0.79
Signal Transduction in Astrocytes during Chronic or Acute Treatment with Drugs (SSRIs, Antibipolar Drugs, GABA-ergic Drugs, and Benzodiazepines) Ameliorating Mood Disorders. J Signal Transduct (2014) 0.79
Differential modulation of emotion processing brain regions by noradrenergic and serotonergic antidepressants. Psychopharmacology (Berl) (2011) 0.78
Predicting therapeutic response to secondary treatment with bupropion: dichotic listening tests of functional brain asymmetry. Psychiatry Res (2007) 0.78
Differential abnormalities of functional connectivity of the amygdala and hippocampus in unipolar and bipolar affective disorders. J Affect Disord (2014) 0.77
Brain Structural Effects of Antidepressant Treatment in Major Depression. Curr Neuropharmacol (2015) 0.76
Tissue Type-Specific Bioenergetic Abnormalities in Adults with Major Depression. Neuropsychopharmacology (2016) 0.75
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 11.84
Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med (2007) 8.07
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85
Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry (2006) 3.66
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry (2003) 3.14
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry (2010) 2.98
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry (2012) 2.74
A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry (2005) 2.59
A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry (2007) 2.45
Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry (2006) 2.29
The poor prognosis of childhood-onset bipolar disorder. J Pediatr (2007) 2.26
Regional cerebral glucose utilization in patients with a range of severities of unipolar depression. Biol Psychiatry (2002) 2.26
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology (2012) 2.17
Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry (2008) 2.17
Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study. J Clin Psychiatry (2009) 2.11
Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry (2006) 2.09
Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Psychiatry (2014) 2.07
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry (2013) 1.97
Early physical and sexual abuse associated with an adverse course of bipolar illness. Biol Psychiatry (2002) 1.93
Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry (2004) 1.92
Association study of 21 circadian genes with bipolar I disorder, schizoaffective disorder, and schizophrenia. Bipolar Disord (2009) 1.90
Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Arch Gen Psychiatry (2003) 1.89
Phenomenology of rapid-cycling bipolar disorder: data from the first 500 participants in the Systematic Treatment Enhancement Program. Am J Psychiatry (2004) 1.86
A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry (2006) 1.83
A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry (2012) 1.76
Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord (2007) 1.74
Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry (2003) 1.72
Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry (2002) 1.71
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry (2008) 1.71
Patterns of neural connectivity during an attention bias task moderate associations between early childhood temperament and internalizing symptoms in young adulthood. Biol Psychiatry (2013) 1.68
Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies. J Clin Psychiatry (2003) 1.68
An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry (2005) 1.65
Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci (2004) 1.61
Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry (2008) 1.57
Impaired recognition of facial emotion in mania. Am J Psychiatry (2002) 1.57
The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry (2005) 1.56
Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. J Clin Psychiatry (2009) 1.55
Effects of tryptophan depletion on serum levels of brain-derived neurotrophic factor in unmedicated patients with remitted depression and healthy subjects. Am J Psychiatry (2005) 1.55
Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biol Psychiatry (2005) 1.51
Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. J Clin Psychiatry (2010) 1.51
Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. Bipolar Disord (2008) 1.49
High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry (2002) 1.48
Validation of digital spiral analysis as outcome parameter for clinical trials in essential tremor. Mov Disord (2011) 1.47
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry (2012) 1.47
Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord (2007) 1.46
Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania. Br J Psychiatry (2004) 1.46
Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. Am J Psychiatry (2005) 1.44
Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. J Clin Psychiatry (2003) 1.44
Assessing cognitive function in bipolar disorder: challenges and recommendations for clinical trial design. J Clin Psychiatry (2015) 1.44
Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder. J Clin Psychiatry (2016) 1.43
Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch Gen Psychiatry (2008) 1.42
New designs for studies of the prophylaxis of bipolar disorder. J Clin Psychopharmacol (2002) 1.39
Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: a call to action. Biol Psychiatry (2004) 1.39
Cerebral blood flow in immediate and sustained anxiety. J Neurosci (2007) 1.38
Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev (2007) 1.36
Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry (2009) 1.33
Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression. Biol Psychiatry (2013) 1.31
Juvenile maladaptive aggression: a review of prevention, treatment, and service configuration and a proposed research agenda. J Clin Psychiatry (2006) 1.31
Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry (2004) 1.29
Behavioral predictors of substance-use initiation in adolescents with and without attention-deficit/hyperactivity disorder. Pediatrics (2006) 1.29
Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry (2003) 1.25
Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry (2006) 1.24
Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. J Clin Psychiatry (2006) 1.24
Evidence for continuing neuropsychological impairments in depression. J Affect Disord (2004) 1.23
Creativity in familial bipolar disorder. J Psychiatr Res (2005) 1.23
Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol (2014) 1.21
Incidence of childhood-onset bipolar illness in the USA and Europe. Br J Psychiatry (2008) 1.21
Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry (2013) 1.21
A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol (2012) 1.20
Principal components of the Beck Depression Inventory and regional cerebral metabolism in unipolar and bipolar depression. Biol Psychiatry (2002) 1.18
What have we learned about trial design from NIMH-funded pragmatic trials? Neuropsychopharmacology (2010) 1.17
Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry (2005) 1.17
Prefrontal cortical abnormalities in currently depressed versus currently remitted patients with major depressive disorder. Neuroimage (2010) 1.16
Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: the impact of medication. Neuroimage (2009) 1.16
Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Network: a sex-specific phenomenon. Arch Gen Psychiatry (2005) 1.16
Automated subcortical segmentation using FIRST: test-retest reliability, interscanner reliability, and comparison to manual segmentation. Hum Brain Mapp (2012) 1.14
Correlates of 1-year prospective outcome in bipolar disorder: results from the Stanley Foundation Bipolar Network. Am J Psychiatry (2004) 1.13
Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biol Psychiatry (2006) 1.13
Number needed to harm can be clinically useful: a response to Safer and Zito. J Nerv Ment Dis (2013) 1.13
Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry (2006) 1.13
Regional cerebral glucose metabolic abnormalities in bipolar II depression. Biol Psychiatry (2006) 1.13
Acute stress symptoms do not worsen in posttraumatic stress disorder and abuse with a single subanesthetic dose of ketamine. Biol Psychiatry (2012) 1.12
Sleep functioning in relation to mood, function, and quality of life at entry to the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Affect Disord (2008) 1.11
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci (2013) 1.11
Sympathoneural and adrenomedullary functional effects of alpha2C-adrenoreceptor gene polymorphism in healthy humans. Pharmacogenet Genomics (2005) 1.10
Probing for hemispheric specialization for motor skill learning: a transcranial direct current stimulation study. J Neurophysiol (2011) 1.09
Is there progression from irritability/dyscontrol to major depressive and manic symptoms? A retrospective community survey of parents of bipolar children. J Affect Disord (2003) 1.09